HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US

The US Advisory Committee on Immunization Practice recommends routine human papillomavirus (HPV) vaccination at 11–12 years of age, but states that vaccination may be initiated as early as 9 years. Our primary goal was to assess whether initiating HPV vaccination at 9–10 years of age, compared to 11...

Full description

Bibliographic Details
Main Authors: Kunal Saxena, Niranjan Kathe, Poorva Sardana, Lixia Yao, Ya-Ting Chen, Noel T. Brewer
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2022.2161253
_version_ 1797673112491261952
author Kunal Saxena
Niranjan Kathe
Poorva Sardana
Lixia Yao
Ya-Ting Chen
Noel T. Brewer
author_facet Kunal Saxena
Niranjan Kathe
Poorva Sardana
Lixia Yao
Ya-Ting Chen
Noel T. Brewer
author_sort Kunal Saxena
collection DOAJ
description The US Advisory Committee on Immunization Practice recommends routine human papillomavirus (HPV) vaccination at 11–12 years of age, but states that vaccination may be initiated as early as 9 years. Our primary goal was to assess whether initiating HPV vaccination at 9–10 years of age, compared to 11–12, was associated with a higher rate of series completion by 13 years of age, and to identify factors associated with series completion by age 13. The study used vaccine claims and other data from the IBM MarketScan Commercial Claims and Encounters (privately insured) and IBM MarketScan Multi-State Medicaid (publicly insured) databases. Participants were 9–12 years of age and initiated HPV vaccination between January 2006 and December 2018 (publicly insured) or February 2019 (privately insured). Among 100,117 privately insured individuals, those initiating the HPV vaccination series at 9–10 years of age had a significantly higher series completion rate by 13 years of age than did those initiating at 11–12 years of age (76.2% versus 48.1%; p < .001). The same pattern was observed for 115,863 publicly insured individuals (70.4% versus 40.0%; p < .001). Provider and health care plan type, female sex, race/ethnicity, and wellness checks or non-HPV vaccinations during the baseline period were significantly associated with series completion by 13 years of age. Proactive initiation of HPV vaccination at 9–10 years of age was associated with higher rates of series completion by 13 years of age. These findings can inform provider education and other interventions to encourage timely HPV vaccination series completion.
first_indexed 2024-03-11T21:39:47Z
format Article
id doaj.art-71581746450949cdbbfe045f9a209eaa
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T21:39:47Z
publishDate 2023-01-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-71581746450949cdbbfe045f9a209eaa2023-09-26T13:25:47ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-01-0119110.1080/21645515.2022.21612532161253HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the USKunal Saxena0Niranjan Kathe1Poorva Sardana2Lixia Yao3Ya-Ting Chen4Noel T. Brewer5Merck & Co., IncComplete HEOR Solutions (CHEORS)Complete HEOR Solutions (CHEORS)Merck & Co., IncMerck & Co., IncGillings School of Global Public Health, University of North CarolinaThe US Advisory Committee on Immunization Practice recommends routine human papillomavirus (HPV) vaccination at 11–12 years of age, but states that vaccination may be initiated as early as 9 years. Our primary goal was to assess whether initiating HPV vaccination at 9–10 years of age, compared to 11–12, was associated with a higher rate of series completion by 13 years of age, and to identify factors associated with series completion by age 13. The study used vaccine claims and other data from the IBM MarketScan Commercial Claims and Encounters (privately insured) and IBM MarketScan Multi-State Medicaid (publicly insured) databases. Participants were 9–12 years of age and initiated HPV vaccination between January 2006 and December 2018 (publicly insured) or February 2019 (privately insured). Among 100,117 privately insured individuals, those initiating the HPV vaccination series at 9–10 years of age had a significantly higher series completion rate by 13 years of age than did those initiating at 11–12 years of age (76.2% versus 48.1%; p < .001). The same pattern was observed for 115,863 publicly insured individuals (70.4% versus 40.0%; p < .001). Provider and health care plan type, female sex, race/ethnicity, and wellness checks or non-HPV vaccinations during the baseline period were significantly associated with series completion by 13 years of age. Proactive initiation of HPV vaccination at 9–10 years of age was associated with higher rates of series completion by 13 years of age. These findings can inform provider education and other interventions to encourage timely HPV vaccination series completion.http://dx.doi.org/10.1080/21645515.2022.2161253human papillomavirushpv vaccinesvaccination schedulesimmunization practicesadolescents
spellingShingle Kunal Saxena
Niranjan Kathe
Poorva Sardana
Lixia Yao
Ya-Ting Chen
Noel T. Brewer
HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
Human Vaccines & Immunotherapeutics
human papillomavirus
hpv vaccines
vaccination schedules
immunization practices
adolescents
title HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
title_full HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
title_fullStr HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
title_full_unstemmed HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
title_short HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
title_sort hpv vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the us
topic human papillomavirus
hpv vaccines
vaccination schedules
immunization practices
adolescents
url http://dx.doi.org/10.1080/21645515.2022.2161253
work_keys_str_mv AT kunalsaxena hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus
AT niranjankathe hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus
AT poorvasardana hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus
AT lixiayao hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus
AT yatingchen hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus
AT noeltbrewer hpvvaccineinitiationat9or10yearsofageandbetterseriescompletionbyage13amongprivatelyandpubliclyinsuredchildrenintheus